[go: up one dir, main page]

CO2018013559A2 - Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds) - Google Patents

Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds)

Info

Publication number
CO2018013559A2
CO2018013559A2 CONC2018/0013559A CO2018013559A CO2018013559A2 CO 2018013559 A2 CO2018013559 A2 CO 2018013559A2 CO 2018013559 A CO2018013559 A CO 2018013559A CO 2018013559 A2 CO2018013559 A2 CO 2018013559A2
Authority
CO
Colombia
Prior art keywords
apds
trifluoroethyl
treatment
specific
kinase delta
Prior art date
Application number
CONC2018/0013559A
Other languages
English (en)
Inventor
Rodger Anthony Allen
Andrew Charles Payne
Martin John Armstrong
Marina Cavazzana
Sven Kracker
Duncan Philip Mchale
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CO2018013559A2 publication Critical patent/CO2018013559A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

N-{(R)-1-[8-Cloro-2-(1-oxipiridin-3-il)-quinolin-3-il]-2,2,2-trifluoroetil}-pirido[3,2-d] La pirimidin-4-ilamina es efectiva en el tratamiento y/o prevención del síndrome de fosfoinositida 3-cinasa delta activada (APDS).
CONC2018/0013559A 2016-05-19 2018-12-13 Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds) CO2018013559A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1608797.5A GB201608797D0 (en) 2016-05-19 2016-05-19 Therapeutic use
PCT/EP2017/061567 WO2017198590A1 (en) 2016-05-19 2017-05-15 A specific trifluoroethyl quinoline analogue for use in the treatment of apds

Publications (1)

Publication Number Publication Date
CO2018013559A2 true CO2018013559A2 (es) 2019-02-28

Family

ID=56369612

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013559A CO2018013559A2 (es) 2016-05-19 2018-12-13 Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds)

Country Status (18)

Country Link
US (1) US20190209567A1 (es)
EP (1) EP3458065A1 (es)
JP (1) JP2019516703A (es)
KR (1) KR20190009790A (es)
CN (1) CN109152783A (es)
AR (1) AR108500A1 (es)
AU (1) AU2017267172A1 (es)
BR (1) BR112018072450A2 (es)
CA (1) CA3023974A1 (es)
CL (1) CL2018003281A1 (es)
CO (1) CO2018013559A2 (es)
EA (1) EA201892638A1 (es)
GB (1) GB201608797D0 (es)
IL (1) IL262943A (es)
MX (1) MX2018013770A (es)
RU (1) RU2018144187A (es)
SG (1) SG11201809396SA (es)
WO (1) WO2017198590A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
CA2944611A1 (en) * 2014-05-27 2015-12-03 Almirall, S.A. Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile

Also Published As

Publication number Publication date
AR108500A1 (es) 2018-08-29
GB201608797D0 (en) 2016-07-06
JP2019516703A (ja) 2019-06-20
SG11201809396SA (en) 2018-11-29
AU2017267172A1 (en) 2018-12-13
US20190209567A1 (en) 2019-07-11
WO2017198590A1 (en) 2017-11-23
RU2018144187A3 (es) 2020-06-19
IL262943A (en) 2018-12-31
RU2018144187A (ru) 2020-06-19
EP3458065A1 (en) 2019-03-27
CN109152783A (zh) 2019-01-04
CA3023974A1 (en) 2017-11-23
MX2018013770A (es) 2019-03-21
BR112018072450A2 (pt) 2019-02-19
KR20190009790A (ko) 2019-01-29
CL2018003281A1 (es) 2019-01-25
EA201892638A1 (ru) 2019-06-28

Similar Documents

Publication Publication Date Title
CO2018013559A2 (es) Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds)
HUE053704T2 (hu) 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
EP3495400A4 (en) BLOCK COPOLYMERS AND SURFACE TREATMENTS THEREFOR
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
HUE037558T2 (hu) Imidazo[4,5-c]kinolin-2-on vegyületek és alkalmazásuk rák kezelésében
EP3501527C0 (en) COMPOSITION FOR PREVENTING OR TREATING A MENTAL DISORDER, CONTAINING A VESICLE DERIVED FROM BACTERIA OF AN ELACTOBACILLUS SPECIES
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
AU2015286721B2 (en) Influenza virus vaccines and uses thereof
CL2013002003A1 (es) Compuestos derivados de 1, 2, 4-triazolo [4,3-a] quinoxalina, inhibidores de pde2 y/o 10; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para en el trastamiento de enfermedades del snc
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
HUE060882T2 (hu) Naftiridinon-származékok és alkalmazásuk arrhytmia kezelésében
EP3566702A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIA, CONSISTING OF BAICALEIN AS THE ACTIVE SUBSTANCE
WO2015148768A3 (en) Onconase for use in treating or preventing viral infections
WO2017143115A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
EP3552606A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CAFFEINE DEPENDENCE CONTAINING AN EXTRACT OF EUODIA OR EVODIAMINE AS ACTIVE SUBSTANCE
CY1122572T1 (el) Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
EP3493811A4 (en) SMALL MOLECULAR THERAPEUTIC COMPOUNDS REDUCING THE INCIDENCE OF INTRACEREBRAL BLEEDING AND CEREBRAL MICROHEMORRHAGE
WO2017129577A8 (en) Ophthalmic gabapentin for the treatment of corneal ulcers
HUE057646T2 (hu) Tirotricin testszag kezelésében és/vagy megelõzésében történõ alkalmazásra, és erre szolgáló készítmények
EP3551208A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALOPECIA COMPRISING AN EXTRACT OF EREMOCHLOA OPHIUROIDES OR FRACTIONS THEREOF AS ACTIVE INGREDIENT
EA201992210A1 (ru) Предотвращение и/или лечение воспалительного заболевания кожи
IT201700109607A1 (it) Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma.
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario